{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:43:42Z","timestamp":1793069022066,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.xphs.2020.10.026","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T11:34:31Z","timestamp":1602761671000},"page":"654-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Cyclodextrins in Parenteral Formulations"],"prefix":"10.1016","volume":"110","author":[{"given":"Thorsteinn","family":"Loftsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2020.10.026_bib1","series-title":"European Pharmacopoeia","year":"2020"},{"key":"10.1016\/j.xphs.2020.10.026_bib2","series-title":"USP43-NF38 6405","year":"2020"},{"key":"10.1016\/j.xphs.2020.10.026_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/03639045.2018.1483392","article-title":"Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics","volume":"44","author":"Rayaprolu","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0169-409X(95)00112-K","article-title":"A\u00a0case for prodrugs: Fosphenytoin","volume":"19","author":"Stella","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.10.026_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.msec.2018.11.031","article-title":"Cyclodextrin-based delivery systems for cancer treatment","volume":"96","author":"Zhang","year":"2019","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.xphs.2020.10.026_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms20030642","article-title":"Cyclodextrin-drug inclusion complexes: in\u00a0vivo and in\u00a0vitro approaches","volume":"20","author":"Carneiro","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23051161","article-title":"Solubility of cyclodextrins and drug\/cyclodextrin complexes","volume":"23","author":"Saokham","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2020.10.026_bib8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2174\/1381612824666171218125431","article-title":"Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art","volume":"24","author":"Conceicao","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.xphs.2020.10.026_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.12917","article-title":"Cyclodextrin-based formulations: a non-invasive platform for targeted drug delivery","volume":"122","author":"Muankaew","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.xphs.2020.10.026_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2016.10.062","article-title":"\u03b3-Cyclodextrin","volume":"516","author":"Saokham","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib13","doi-asserted-by":"crossref","first-page":"119396","DOI":"10.1016\/j.ijpharm.2020.119396","article-title":"Sulfobutylether-\u03b2-cyclodextrin","volume":"583","author":"Stella","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib14","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.xphs.2018.03.021","article-title":"Role of cyclodextrins in nanoparticle-based drug delivery systems","volume":"107","author":"Shelley","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib15","doi-asserted-by":"crossref","first-page":"119181","DOI":"10.1016\/j.ijpharm.2020.119181","article-title":"Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: a review","volume":"579","author":"Mura","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib16","article-title":"Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies","volume":"10","author":"Santos","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.xphs.2020.10.026_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115805","article-title":"Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: a review","volume":"232","author":"Tian","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2020.10.026_bib18","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","article-title":"Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization","volume":"85","author":"Loftsson","year":"1996","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib19","first-page":"117","article-title":"Phase-solubility techniques","volume":"vol. 4","author":"Higuchi","year":"1965"},{"key":"10.1016\/j.xphs.2020.10.026_bib20","first-page":"404","article-title":"Aqueous solubility and true solutions","volume":"65","author":"Loftsson","year":"2010","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2020.10.026_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.02.004","article-title":"Self-association of cyclodextrins and cyclodextrin complexes in aqueous solutions","volume":"560","author":"Loftsson","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10847-006-9247-2","article-title":"The complexation efficiency","volume":"57","author":"Loftsson","year":"2007","journal-title":"J\u00a0Inclusion Phenom Macrocycl Chem"},{"key":"10.1016\/j.xphs.2020.10.026_bib23","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/jps.23077","article-title":"Cyclodextrins as functional excipients: methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1208\/s12249-009-9205-6","article-title":"Drug targeting to the hair follicles: a cyclodextrin-based drug delivery","volume":"10","author":"Konradsdottir","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2020.10.026_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2017.12.014","article-title":"The effect of 2-hydroxypropyl-\u03b2-cyclodextrin on the intestinal permeation through mucus","volume":"114","author":"Stappaerts","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib26","first-page":"1000","article-title":"Particulate matter in injectables: main cause for recalls","volume":"3","author":"Tawde","year":"2014","journal-title":"J\u00a0Pharmacovigil"},{"key":"10.1016\/j.xphs.2020.10.026_bib27","volume":"Vol. 6056941 6","author":"Schramm","year":"2000"},{"key":"10.1016\/j.xphs.2020.10.026_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijpharm.2018.05.048","article-title":"Novel excipients - regulatory challenges and perspectives - the EU insight","volume":"546","author":"Kozarewicz","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib29","series-title":"Questions and Answers on Cyclodextrins Used as Excipients in Medicinal Products for Human Use","year":"2017"},{"key":"10.1016\/j.xphs.2020.10.026_bib30","series-title":"Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications","first-page":"91","article-title":"Recent findings on safety profiles of cyclodextrins, cyclodextrin conjugates, and polypseudorotaxanes","author":"Arima","year":"2011"},{"key":"10.1016\/j.xphs.2020.10.026_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.reprotox.2015.05.010","article-title":"Juvenile animal testing of hydroxypropyl-\u03b2-cyclodextrin in support of pediatric drug development","volume":"56","author":"De Schaepdrijver","year":"2015","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.xphs.2020.10.026_bib32","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.xphs.2020.10.026_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.xphs.2020.10.026_bib34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","article-title":"Cyclodextrins","volume":"453","author":"Kurkov","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2016.10.062","article-title":"\u03b3-Cyclodextrin","volume":"516","author":"Saokham","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40268-016-0123-2","article-title":"Efficacy and safety profile of diclofenac\/cyclodextrin and progesterone\/cyclodextrin formulations: a review of the literature data","volume":"16","author":"Scavone","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.xphs.2020.10.026_bib37","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.xphs.2019.01.004","article-title":"Cyclodextrin reduces intravenous toxicity of a model compound","volume":"108","author":"Mantik","year":"2019","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib38","series-title":"Essential Pharmacokinetics: A Primer for Pharmaceutical Scientists","author":"Loftsson","year":"2015"},{"key":"10.1016\/j.xphs.2020.10.026_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2015.01.022","article-title":"Excipient pharmacokinetics and profiling","volume":"480","author":"Loftsson","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib40","first-page":"111","article-title":"Pharmacokinetics of dextrans","volume":"6","author":"Deux","year":"2001","journal-title":"Curr Trends Polym Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib41","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2215\/CJN.09400913","article-title":"The glomerulus: the sphere of influence","volume":"9","author":"Pollak","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xphs.2020.10.026_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(03)00224-2","article-title":"Effect of copolymer composition on the physicochemical characteristics, in\u00a0vitro stability, and biodistribution of PLGA-mPEG nanoparticles","volume":"259","author":"Avgoustakis","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib43","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1021\/nn1018818","article-title":"Physiologically based pharmacokinetic modeling of nanoparticles","volume":"4","author":"Li","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2020.10.026_bib44","series-title":"Nanotechnology. Materials, Methodologies, and Assessments","first-page":"97","article-title":"Pharmacokinetics and pharmacodynamics of nanomaterials","author":"Marcato","year":"2014"},{"key":"10.1016\/j.xphs.2020.10.026_bib45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/j.1552-4604.1998.tb04465.x","article-title":"A\u00a0pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection","volume":"38","author":"Zhou","year":"1998","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2020.10.026_bib46","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2020.10.026_bib47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jphp.12427","article-title":"Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug\/cyclodextrin complexes","volume":"68","author":"Loftsson","year":"2016","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2020.10.026_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2020.10.026_bib49","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/jps.23195","article-title":"Comparative canine pharmacokinetics-pharmacodynamics of fospropofol disodium injection, propofol emulsion, and cyclodextrin-enabled propofol solution following bolus parenteral administration","volume":"101","author":"McIntosh","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1213\/01.ANE.0000066019.42467.7A","article-title":"The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model","volume":"97","author":"Egan","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2020.10.026_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1081\/PDT-200031428","article-title":"Toward the development of an injectable dosage form of propofol: preparation and evaluation of propofol-sulfobutyl ether 7-beta-cyclodextrin complex","volume":"9","author":"Babu","year":"2004","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2020.10.026_bib52","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1213\/ANE.0000000000000559","article-title":"Alphaxalone reformulated: a water-soluble intravenous anesthetic preparation in sulfobutyl-ether-\u03b2-cyclodextrin","volume":"120","author":"Goodchild","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2020.10.026_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0378-5173(90)90113-I","article-title":"The use of 2-hydroxypropyl-\u03b2-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs","volume":"59","author":"Dietzel","year":"1990","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/10717540601036880","article-title":"Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs","volume":"14","author":"Chen","year":"2007","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xphs.2020.10.026_bib55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejpb.2008.05.012","article-title":"Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice","volume":"70","author":"Ben Zirar","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03639040500214738","article-title":"Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use","volume":"31","author":"Holvoet","year":"2005","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2020.10.026_bib57","first-page":"598","article-title":"Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use","volume":"60","author":"Holvoet","year":"2005","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2020.10.026_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1081\/PDT-100100548","article-title":"Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-beta-cyclodextrin","volume":"5","author":"Blanchard","year":"2000","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2020.10.026_bib59","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1208\/s12249-010-9482-0","article-title":"Parenteral delivery of HP\u03b2CD: effects on drug-HSA binding","volume":"11","author":"Kurkov","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2020.10.026_bib60","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1002\/jps.23329","article-title":"The effect of parenterally administered cyclodextrins on the pharmacokinetics of coadministered drugs","volume":"101","author":"Kurkov","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib61","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1021\/ja045541t","article-title":"Solutes probe hydration in specific association of cyclodextrin and adamantane","volume":"127","author":"Harries","year":"2005","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.xphs.2020.10.026_bib62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jps.20525","article-title":"The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins","volume":"95","author":"Perry","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib63","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/jps.24331","article-title":"The effect of intravenous sulfobutylether7 -\u03b2-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds","volume":"104","author":"Leong","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib64","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/jps.23177","article-title":"Probing a potential in\u00a0vivo drug-excipient interaction: temporal effects of a modified \u03b2-cyclodextrin on the intravenous pharmacokinetics of a model high-affinity drug ligand","volume":"101","author":"Mannila","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib65","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-016-0604-1","article-title":"Sugammadex: a review of neuromuscular blockade reversal","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"issue":"5 Pt 1","key":"10.1016\/j.xphs.2020.10.026_bib66","doi-asserted-by":"crossref","first-page":"51904","DOI":"10.1103\/PhysRevE.82.051904","article-title":"Universal patterns of equilibrium cluster growth in aqueous sugars observed by dynamic light scattering","volume":"82","author":"Sidebottom","year":"2010","journal-title":"Phys Rev E Stat Nonlin Soft Matter Phys"},{"key":"10.1016\/j.xphs.2020.10.026_bib67","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jpcb.8b07623","article-title":"Kirkwood\u2212buff-derived alcohol parameters for aqueous carbohydrates and their application to preferential interaction coefficient calculations of proteins","author":"Cloutier","year":"2018","journal-title":"J\u00a0Phys Chem B"},{"key":"10.1016\/j.xphs.2020.10.026_bib68","doi-asserted-by":"crossref","first-page":"11948","DOI":"10.1021\/jp0749120","article-title":"Carbohydrate clustering in aqueous solutions and the dynamics of confined water","volume":"111","author":"Sonoda","year":"2007","journal-title":"J\u00a0Phys Chem B"},{"key":"10.1016\/j.xphs.2020.10.026_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.carbpol.2013.08.021","article-title":"Challenges in analysis of high-molar mass dextrans: comparison of HPSEC, AsFlFFF and DOSY NMR spectroscopy","volume":"99","author":"Maina","year":"2014","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2020.10.026_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ma11101971","article-title":"2-Hydroxypropyl--Cyclodextrin aggregates: identification and development of analytical techniques","volume":"11","author":"Couto","year":"2018","journal-title":"Materials"},{"key":"10.1016\/j.xphs.2020.10.026_bib71","first-page":"307","article-title":"Self-assembly of cyclodextrin complexes: detection, obstacles and benefits","volume":"75","author":"Muankaew","year":"2020","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2020.10.026_bib72","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/js970178s","article-title":"Inclusion complexation of propofol with 2-hydroxypropyl-beta-cyclodextrin. Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat. trapani@ippo.uniba.it","volume":"87","author":"Trapani","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1213\/01.ANE.0000066019.42467.7A","article-title":"The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model","volume":"97","author":"Egan","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2020.10.026_bib74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2004.02.028","article-title":"Evaluation of new propofol aqueous solutions for intravenous anesthesia","volume":"278","author":"Trapani","year":"2004","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1213\/ANE.0b013e31822b8648","article-title":"Propofol in a modified cyclodextrin formulation: first human study of dose-response with emphasis on injection pain","volume":"113","author":"Wallentine","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2020.10.026_bib76","first-page":"395","article-title":"Fospropofol disodium (lusedra) injection for anesthesia-care sedation: a clinical review","volume":"37","author":"Boules","year":"2012","journal-title":"P\u00a0T"},{"key":"10.1016\/j.xphs.2020.10.026_bib77","volume":"vol. 2020","year":"2020"},{"key":"10.1016\/j.xphs.2020.10.026_bib78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/js9602913","article-title":"Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions","volume":"86","author":"Brewster","year":"1997","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1528-1157.1997.tb01084.x","article-title":"Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus","volume":"38","author":"Loscher","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.xphs.2020.10.026_bib80","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jps.2600660724","article-title":"Solubility and ionization characteristics of phenytoin","volume":"66","author":"Schwartz","year":"1977","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0939-6411(01)00144-8","article-title":"Complexation of phenytoin with some hydrophilic cyclodextrins: effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice","volume":"52","author":"Latrofa","year":"2001","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/js980041h","article-title":"Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)(7m)-beta-CD","volume":"87","author":"Narisawa","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib83","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/js980109t","article-title":"Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether","volume":"87","author":"Kim","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/A:1011041628797","article-title":"Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)(7M)-beta-CD to HP-beta-CD","volume":"18","author":"Zia","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2020.10.026_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1008094702632","article-title":"Interaction of hydroxy acids with beta-cyclodextrin","volume":"33","author":"Fenyvesi","year":"1999","journal-title":"J\u00a0Inclusion Phenom Macrocycl Chem"},{"key":"10.1016\/j.xphs.2020.10.026_bib86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0378-5173(03)00265-5","article-title":"Ternary systems of naproxen with hydroxypropyl-beta-cyclodextrin and aminoacids","volume":"260","author":"Mura","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.10.026_bib87","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the Interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib88","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10847-006-9249-0","article-title":"Solubilization of itraconazole as a function of cyclodextrin structural space","volume":"57","author":"Brewster","year":"2007","journal-title":"J\u00a0Inclusion Phenom Macrocycl Chem"},{"key":"10.1016\/j.xphs.2020.10.026_bib89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2008.02.007","article-title":"Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions","volume":"34","author":"Brewster","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib90","first-page":"217","article-title":"Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions","volume":"63","author":"Brewster","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2020.10.026_bib91","series-title":"Cyclodextrins: Synthesis, Chemical Applications and Role in Drug Delivery","first-page":"293","article-title":"Sulfobutylether-cyclodextrins: structure, degree of substitution and functional performance","author":"Pusk\u00e1s","year":"2015"},{"key":"10.1016\/j.xphs.2020.10.026_bib92","first-page":"409","article-title":"Study of physicochemical parameters affecting the release of diclofenac sodium from lipophilic matrix tablets","volume":"51","author":"Kincl","year":"2004","journal-title":"Acta Chim Slov"},{"key":"10.1016\/j.xphs.2020.10.026_bib93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ardp.19843170314","article-title":"pH-solubility relationship and partition coefficients for some anti-inflammatory arylaliphatic acids","volume":"317","author":"Chiarini","year":"1984","journal-title":"Arch Pharm Pharm Med Chem"},{"key":"10.1016\/j.xphs.2020.10.026_bib94","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1039\/a902526j","article-title":"Evidence of the existence of 2:1 guest-host complexes between diclofenac and cyclodextrins in D2O solutions. A 1H and 13C NMR study on diclofenac\/\u03b2-cyclodextrin and diclofenac\/2-hydroxypropyl-\u03b2-cyclodextrin systems","author":"Mucci","year":"1999","journal-title":"J\u00a0Chem Res"},{"issue":"3","key":"10.1016\/j.xphs.2020.10.026_bib95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0168-8278(96)80119-X","article-title":"Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis","volume":"25","author":"Terg","year":"1996","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.xphs.2020.10.026_bib96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003088-198712020-00003","article-title":"Clinical pharmacokinetic considerations in the use of plasma expanders","volume":"12","author":"Klotz","year":"1987","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2020.10.026_bib97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/cs0400137","article-title":"Human glomerular membrane porosity and filtration pressure: dextran clearance data analysed by theoretical models","volume":"40","author":"Arturson","year":"1971","journal-title":"Clin Sci"},{"key":"10.1016\/j.xphs.2020.10.026_bib98","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jps.2600840706","article-title":"Dose dependency of the kinetics of dextrans in rats: effects of molecular weight","volume":"84","author":"Mehvar","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2020.10.026_bib99","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jps.2600810914","article-title":"Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats","volume":"81","author":"Mehvar","year":"1992","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2020.10.026_bib100","article-title":"Inclusion complexes of aryl-heterocyclic salts","author":"Kim","year":"2001","journal-title":"US Patent No. 6,232,304"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920306183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920306183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:33:35Z","timestamp":1758360815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920306183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022354920306183"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.10.026","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclodextrins in Parenteral Formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}